Compared to normal groups, promoter hypomethylation of DDX20 gene occurred in the primary tumor group (Figure 4(a)) Compared with LICH patients without TP53 mutations (n = 266), a significantly low promoter methylated of DDX20 in patients with mutations in TP53 (n = 109) was found (Figure 4(b)) In addition, promoter hypomethylation of DDX20 in liver cancer patients was significantly decreased with tumor pathological grade (Figure 4(c)). The gene discussed is TP53; the disease is neoplasm.